{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":"Activist Defense","value":72},{"name":"Capital Markets","value":26},{"name":"Construction and Procurement","value":40},{"name":"Corporate Governance","value":27},{"name":"Emerging Companies and Venture Capital","value":80},{"name":"Employee Benefits and Executive Compensation","value":28},{"name":"Energy and Infrastructure Projects","value":35},{"name":"Financial Restructuring","value":10},{"name":"Fund Finance","value":134},{"name":"Global Human Capital and Compliance ","value":121},{"name":"Investment Funds and Asset Management","value":78},{"name":"Leveraged Finance","value":29},{"name":"Mergers and Acquisitions (M\u0026A)","value":32},{"name":"Middle East and Islamic Finance and Investment","value":31},{"name":"Private Equity","value":33},{"name":"Public Companies","value":126},{"name":"Real Estate","value":36},{"name":"Structured Finance and Securitization","value":82},{"name":"Tax","value":37},{"name":"Technology Transactions","value":115},{"name":"Government Matters","value":"cg-2"},{"name":"Antitrust","value":1},{"name":"Data, Privacy and Security","value":6},{"name":"Environmental, Health and Safety","value":71},{"name":"FDA and Life Sciences","value":21},{"name":"Government Advocacy and Public Policy","value":23},{"name":"Government Contracts","value":116},{"name":"Healthcare","value":24},{"name":"Innovation Protection","value":135},{"name":"International Trade","value":25},{"name":"National Security and Corporate Espionage","value":110},{"name":"Securities Enforcement and Regulation","value":20},{"name":"Special Matters and Government Investigations","value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":"Antitrust ","value":129},{"name":"Appellate, Constitutional and Administrative Law","value":2},{"name":"Bankruptcy and Insolvency Litigation","value":38},{"name":"Class Action Defense","value":3},{"name":"Commercial Litigation","value":5},{"name":"Corporate and Securities Litigation","value":19},{"name":"E-Discovery","value":7},{"name":"Global Construction and Infrastructure Disputes","value":4},{"name":"Innovation Protection","value":136},{"name":"Intellectual Property","value":13},{"name":"International Arbitration and Litigation","value":14},{"name":"Labor and Employment","value":15},{"name":"Product Liability","value":17},{"name":"Professional Liability","value":18},{"name":"Toxic \u0026 Environmental Torts","value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":"Artificial Intelligence (AI) and Machine Learning","value":133},{"name":"Automotive, Transportation and Mobility","value":106},{"name":"Buy American","value":124},{"name":"Crisis Management","value":111},{"name":"Doing Business in Latin America","value":132},{"name":"Energy Transition","value":131},{"name":"Energy","value":102},{"name":"Environmental Agenda","value":125},{"name":"Environmental, Social and Governance (ESG)","value":127},{"name":"Financial Services","value":107},{"name":"Focus on Women's Health","value":112},{"name":"Food and Beverage","value":105},{"name":"Higher Education","value":109},{"name":"Life Sciences and Healthcare","value":103},{"name":"Russia/Ukraine","value":128},{"name":"Special Purpose Acquisition Companies (SPACs)","value":123},{"name":"Technology","value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"23","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"M","per_page":12,"people":[{"id":442384,"version":1,"owner_type":"Person","owner_id":966,"payload":{"bio":"\u003cp\u003eChris Markus focuses on U.S. federal and state regulation of drugs, biologics, biotechnology and related products. As a partner in our FDA and Life Sciences practice and Deputy Practice Group Leader, Chris represents clients in a range of regulatory strategy and compliance evaluations, enforcement matters, and business transactions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eChris represents drug, biologic and other healthcare products companies and investors with compliance and enforcement under the Food and Drug Administration, the Drug Enforcement Administration (DEA) and related state agencies such as Boards of Pharmacy. She also represents clients in business transactions, including strategic planning, due diligence and assessment, that involve product development and approval, safety, labeling, marketing and advertising, manufacturing and supply chain.\u003c/p\u003e\n\u003cp\u003eBased on her experience, Chris was chosen to serve as the legal member of the Institute of Medicine's Committee on Pediatric Studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. IOM evaluated studies of drugs and biologics performed under two statutory regimes that provide incentives and, in some instances, mandate pediatric research through the drug approval process. The Committee assessed the findings and offered recommendations and briefings to FDA and the U.S. Congress.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eChris has been recognized by the\u0026nbsp;\u003cem\u003eBTI Consulting Group\u003c/em\u003e\u0026nbsp;as a 2017 \"Client Service All-Star\" and named repeatedly as a \"Life Sciences Star\" by\u0026nbsp;\u003cem\u003eLMG Life Sciences.\u003c/em\u003e\u0026nbsp; She continues to be identified as one of\u0026nbsp;\u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;for FDA Law, and ranked as a life sciences practitioner by\u0026nbsp;\u003cem\u003eThe Legal 500\u003c/em\u003e.\u003c/p\u003e","slug":"christina-markus","email":"cmarkus@kslaw.com","phone":null,"matters":["\u003cp\u003eAdvised numerous pharmaceutical and device manufacturers and distributors on compliance with\u0026nbsp;\u003cstrong\u003estate laws\u003c/strong\u003e\u0026nbsp;governing operating entity licensure (including for \"virtual\" companies), extended producer responsibility (drug and sharps take back laws) and product distribution monitoring and reporting.\u003c/p\u003e","\u003cp\u003eAdvised on range of clinical trial issues, including design, compliance and transparency disclosures.\u003c/p\u003e","\u003cp\u003eDeveloped responses to inspectional findings and import alerts, in close collaboration with technical experts.\u003c/p\u003e","\u003cp\u003eAdvised on the Prescription Drug Marketing Act (PDMA) and state-specific requirements concerning the distribution and reporting of prescription, over-the-counter, and controlled drug samples.\u003c/p\u003e","\u003cp\u003eAdvised\u0026nbsp;\u003cstrong\u003edozens of pharmaceutical and biological product companies\u003c/strong\u003e, and investors, on life cycle issues, including patent and market exclusivity eligibility, regulatory strategies, and transactional diligence.\u003c/p\u003e","\u003cp\u003eDeveloped and responded to citizen petition elucidating legal and scientific concerns about FDA's proposed\u0026nbsp;\u003cstrong\u003ebioequivalence standards, Hatch-Waxman 30-month stay provisions\u003c/strong\u003e, and other key regulatory topics.\u003c/p\u003e","\u003cp\u003ePerformed due diligence for\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eregulatory issues\u003c/strong\u003e\u0026nbsp;and supported negotiation for corporate licensing, M\u0026amp;A, equity investing and financial institution lending.\u003c/p\u003e","\u003cp\u003eEvaluated\u0026nbsp;\u003cstrong\u003eimpacts of the Drug Supply Chain Security Act (DSCSA)\u003c/strong\u003e\u0026nbsp;on manufacturers, distributors, and third-party logistics providers of drugs, medical devices and combination products.\u003c/p\u003e","\u003cp\u003eDefended\u0026nbsp;\u003cstrong\u003eproduct distributors\u003c/strong\u003e\u0026nbsp;against proposed disciplinary action by the California Board of Pharmacy; Alabama Board of Pharmacy, and other jurisdictions.\u003c/p\u003e","\u003cp\u003eAdvised on the status and use of controlled substances\u0026nbsp;\u003cstrong\u003eand listed chemicals\u003c/strong\u003e, including:\u003c/p\u003e\n\u003cp\u003e- Administrative hearings concerning applicants for registration to import narcotic raw materials,\u003c/p\u003e\n\u003cp\u003e- Representation of a reverse distributor before DEA and state agencies to untangle registration issues arising in a multi-faceted corporate transaction, without penalty to the acquiring company,\u003c/p\u003e\n\u003cp\u003e- Applied listed chemical requirements impacting an industrial chemical importer's supply chain, and\u003c/p\u003e\n\u003cp\u003e- Facilitated DEA scheduling of a new chemical entity completing the FDA approval process.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":21,"guid":"21.capabilities","index":0,"source":"capabilities"},{"id":3,"guid":"3.smart_tags","index":1,"source":"smartTags"},{"id":107,"guid":"107.capabilities","index":2,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":3,"source":"smartTags"},{"id":105,"guid":"105.capabilities","index":4,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":5,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":6,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":7,"source":"capabilities"},{"id":13,"guid":"13.capabilities","index":8,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":9,"source":"capabilities"},{"id":33,"guid":"33.capabilities","index":10,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":11,"source":"capabilities"},{"id":114,"guid":"114.capabilities","index":12,"source":"capabilities"},{"id":122,"guid":"122.capabilities","index":13,"source":"capabilities"},{"id":764,"guid":"764.smart_tags","index":14,"source":"smartTags"}],"is_active":true,"last_name":"Markus","nick_name":"Chris","clerkships":[],"first_name":"Christina","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":"M.","name_suffix":"","recognitions":[{"title":"Client Service All-Star (unprompted survey of large company corporate counsel)","detail":"BTI Consulting, 2017"},{"title":"Who's Who Legal: Life Sciences","detail":"2017-2024"},{"title":"Leading Life Sciences Lawyer","detail":"LMG Life Sciences, 2012-2025"},{"title":"Best Lawyers in America - FDA Law","detail":"Best Lawyers/US News \u0026 World Report, 2015-2026"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eChris Markus focuses on U.S. federal and state regulation of drugs, biologics, biotechnology and related products. As a partner in our FDA and Life Sciences practice and Deputy Practice Group Leader, Chris represents clients in a range of regulatory strategy and compliance evaluations, enforcement matters, and business transactions.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eChris represents drug, biologic and other healthcare products companies and investors with compliance and enforcement under the Food and Drug Administration, the Drug Enforcement Administration (DEA) and related state agencies such as Boards of Pharmacy. She also represents clients in business transactions, including strategic planning, due diligence and assessment, that involve product development and approval, safety, labeling, marketing and advertising, manufacturing and supply chain.\u003c/p\u003e\n\u003cp\u003eBased on her experience, Chris was chosen to serve as the legal member of the Institute of Medicine's Committee on Pediatric Studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. IOM evaluated studies of drugs and biologics performed under two statutory regimes that provide incentives and, in some instances, mandate pediatric research through the drug approval process. The Committee assessed the findings and offered recommendations and briefings to FDA and the U.S. Congress.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eChris has been recognized by the\u0026nbsp;\u003cem\u003eBTI Consulting Group\u003c/em\u003e\u0026nbsp;as a 2017 \"Client Service All-Star\" and named repeatedly as a \"Life Sciences Star\" by\u0026nbsp;\u003cem\u003eLMG Life Sciences.\u003c/em\u003e\u0026nbsp; She continues to be identified as one of\u0026nbsp;\u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;for FDA Law, and ranked as a life sciences practitioner by\u0026nbsp;\u003cem\u003eThe Legal 500\u003c/em\u003e.\u003c/p\u003e","matters":["\u003cp\u003eAdvised numerous pharmaceutical and device manufacturers and distributors on compliance with\u0026nbsp;\u003cstrong\u003estate laws\u003c/strong\u003e\u0026nbsp;governing operating entity licensure (including for \"virtual\" companies), extended producer responsibility (drug and sharps take back laws) and product distribution monitoring and reporting.\u003c/p\u003e","\u003cp\u003eAdvised on range of clinical trial issues, including design, compliance and transparency disclosures.\u003c/p\u003e","\u003cp\u003eDeveloped responses to inspectional findings and import alerts, in close collaboration with technical experts.\u003c/p\u003e","\u003cp\u003eAdvised on the Prescription Drug Marketing Act (PDMA) and state-specific requirements concerning the distribution and reporting of prescription, over-the-counter, and controlled drug samples.\u003c/p\u003e","\u003cp\u003eAdvised\u0026nbsp;\u003cstrong\u003edozens of pharmaceutical and biological product companies\u003c/strong\u003e, and investors, on life cycle issues, including patent and market exclusivity eligibility, regulatory strategies, and transactional diligence.\u003c/p\u003e","\u003cp\u003eDeveloped and responded to citizen petition elucidating legal and scientific concerns about FDA's proposed\u0026nbsp;\u003cstrong\u003ebioequivalence standards, Hatch-Waxman 30-month stay provisions\u003c/strong\u003e, and other key regulatory topics.\u003c/p\u003e","\u003cp\u003ePerformed due diligence for\u0026nbsp;\u003cstrong data-redactor-tag=\"strong\"\u003eregulatory issues\u003c/strong\u003e\u0026nbsp;and supported negotiation for corporate licensing, M\u0026amp;A, equity investing and financial institution lending.\u003c/p\u003e","\u003cp\u003eEvaluated\u0026nbsp;\u003cstrong\u003eimpacts of the Drug Supply Chain Security Act (DSCSA)\u003c/strong\u003e\u0026nbsp;on manufacturers, distributors, and third-party logistics providers of drugs, medical devices and combination products.\u003c/p\u003e","\u003cp\u003eDefended\u0026nbsp;\u003cstrong\u003eproduct distributors\u003c/strong\u003e\u0026nbsp;against proposed disciplinary action by the California Board of Pharmacy; Alabama Board of Pharmacy, and other jurisdictions.\u003c/p\u003e","\u003cp\u003eAdvised on the status and use of controlled substances\u0026nbsp;\u003cstrong\u003eand listed chemicals\u003c/strong\u003e, including:\u003c/p\u003e\n\u003cp\u003e- Administrative hearings concerning applicants for registration to import narcotic raw materials,\u003c/p\u003e\n\u003cp\u003e- Representation of a reverse distributor before DEA and state agencies to untangle registration issues arising in a multi-faceted corporate transaction, without penalty to the acquiring company,\u003c/p\u003e\n\u003cp\u003e- Applied listed chemical requirements impacting an industrial chemical importer's supply chain, and\u003c/p\u003e\n\u003cp\u003e- Facilitated DEA scheduling of a new chemical entity completing the FDA approval process.\u003c/p\u003e"],"recognitions":[{"title":"Client Service All-Star (unprompted survey of large company corporate counsel)","detail":"BTI Consulting, 2017"},{"title":"Who's Who Legal: Life Sciences","detail":"2017-2024"},{"title":"Leading Life Sciences Lawyer","detail":"LMG Life Sciences, 2012-2025"},{"title":"Best Lawyers in America - FDA Law","detail":"Best Lawyers/US News \u0026 World Report, 2015-2026"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":1035}]},"capability_group_id":2},"created_at":"2025-11-05T05:04:00.000Z","updated_at":"2025-11-05T05:04:00.000Z","searchable_text":"Markus{{ FIELD }}{:title=\u0026gt;\"Client Service All-Star (unprompted survey of large company corporate counsel)\", :detail=\u0026gt;\"BTI Consulting, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Who's Who Legal: Life Sciences\", :detail=\u0026gt;\"2017-2024\"}{{ FIELD }}{:title=\u0026gt;\"Leading Life Sciences Lawyer\", :detail=\u0026gt;\"LMG Life Sciences, 2012-2025\"}{{ FIELD }}{:title=\u0026gt;\"Best Lawyers in America - FDA Law\", :detail=\u0026gt;\"Best Lawyers/US News \u0026amp; World Report, 2015-2026\"}{{ FIELD }}Advised numerous pharmaceutical and device manufacturers and distributors on compliance with state laws governing operating entity licensure (including for \"virtual\" companies), extended producer responsibility (drug and sharps take back laws) and product distribution monitoring and reporting.{{ FIELD }}Advised on range of clinical trial issues, including design, compliance and transparency disclosures.{{ FIELD }}Developed responses to inspectional findings and import alerts, in close collaboration with technical experts.{{ FIELD }}Advised on the Prescription Drug Marketing Act (PDMA) and state-specific requirements concerning the distribution and reporting of prescription, over-the-counter, and controlled drug samples.{{ FIELD }}Advised dozens of pharmaceutical and biological product companies, and investors, on life cycle issues, including patent and market exclusivity eligibility, regulatory strategies, and transactional diligence.{{ FIELD }}Developed and responded to citizen petition elucidating legal and scientific concerns about FDA's proposed bioequivalence standards, Hatch-Waxman 30-month stay provisions, and other key regulatory topics.{{ FIELD }}Performed due diligence for regulatory issues and supported negotiation for corporate licensing, M\u0026amp;A, equity investing and financial institution lending.{{ FIELD }}Evaluated impacts of the Drug Supply Chain Security Act (DSCSA) on manufacturers, distributors, and third-party logistics providers of drugs, medical devices and combination products.{{ FIELD }}Defended product distributors against proposed disciplinary action by the California Board of Pharmacy; Alabama Board of Pharmacy, and other jurisdictions.{{ FIELD }}Advised on the status and use of controlled substances and listed chemicals, including:\n- Administrative hearings concerning applicants for registration to import narcotic raw materials,\n- Representation of a reverse distributor before DEA and state agencies to untangle registration issues arising in a multi-faceted corporate transaction, without penalty to the acquiring company,\n- Applied listed chemical requirements impacting an industrial chemical importer's supply chain, and\n- Facilitated DEA scheduling of a new chemical entity completing the FDA approval process.{{ FIELD }}Chris Markus focuses on U.S. federal and state regulation of drugs, biologics, biotechnology and related products. As a partner in our FDA and Life Sciences practice and Deputy Practice Group Leader, Chris represents clients in a range of regulatory strategy and compliance evaluations, enforcement matters, and business transactions.\nChris represents drug, biologic and other healthcare products companies and investors with compliance and enforcement under the Food and Drug Administration, the Drug Enforcement Administration (DEA) and related state agencies such as Boards of Pharmacy. She also represents clients in business transactions, including strategic planning, due diligence and assessment, that involve product development and approval, safety, labeling, marketing and advertising, manufacturing and supply chain.\nBased on her experience, Chris was chosen to serve as the legal member of the Institute of Medicine's Committee on Pediatric Studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. IOM evaluated studies of drugs and biologics performed under two statutory regimes that provide incentives and, in some instances, mandate pediatric research through the drug approval process. The Committee assessed the findings and offered recommendations and briefings to FDA and the U.S. Congress. \nChris has been recognized by the BTI Consulting Group as a 2017 \"Client Service All-Star\" and named repeatedly as a \"Life Sciences Star\" by LMG Life Sciences.  She continues to be identified as one of The Best Lawyers in America for FDA Law, and ranked as a life sciences practitioner by The Legal 500. Partner Client Service All-Star (unprompted survey of large company corporate counsel) BTI Consulting, 2017 Who's Who Legal: Life Sciences 2017-2024 Leading Life Sciences Lawyer LMG Life Sciences, 2012-2025 Best Lawyers in America - FDA Law Best Lawyers/US News \u0026amp; World Report, 2015-2026 College of William and Mary William \u0026amp; Mary Law School University of Virginia University of Virginia School of Law District of Columbia Virginia The District of Columbia Bar Virginia State Bar Advised numerous pharmaceutical and device manufacturers and distributors on compliance with state laws governing operating entity licensure (including for \"virtual\" companies), extended producer responsibility (drug and sharps take back laws) and product distribution monitoring and reporting. Advised on range of clinical trial issues, including design, compliance and transparency disclosures. Developed responses to inspectional findings and import alerts, in close collaboration with technical experts. Advised on the Prescription Drug Marketing Act (PDMA) and state-specific requirements concerning the distribution and reporting of prescription, over-the-counter, and controlled drug samples. Advised dozens of pharmaceutical and biological product companies, and investors, on life cycle issues, including patent and market exclusivity eligibility, regulatory strategies, and transactional diligence. Developed and responded to citizen petition elucidating legal and scientific concerns about FDA's proposed bioequivalence standards, Hatch-Waxman 30-month stay provisions, and other key regulatory topics. Performed due diligence for regulatory issues and supported negotiation for corporate licensing, M\u0026amp;A, equity investing and financial institution lending. Evaluated impacts of the Drug Supply Chain Security Act (DSCSA) on manufacturers, distributors, and third-party logistics providers of drugs, medical devices and combination products. Defended product distributors against proposed disciplinary action by the California Board of Pharmacy; Alabama Board of Pharmacy, and other jurisdictions. Advised on the status and use of controlled substances and listed chemicals, including:\n- Administrative hearings concerning applicants for registration to import narcotic raw materials,\n- Representation of a reverse distributor before DEA and state agencies to untangle registration issues arising in a multi-faceted corporate transaction, without penalty to the acquiring company,\n- Applied listed chemical requirements impacting an industrial chemical importer's supply chain, and\n- Facilitated DEA scheduling of a new chemical entity completing the FDA approval process.","searchable_name":"Christina M. Markus (Chris)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":437140,"version":1,"owner_type":"Person","owner_id":7216,"payload":{"bio":"\u003cp\u003eMatthew D. McGill is a leader in arbitral award and judgment enforcement and an accomplished appellate advocate who handles civil litigation appeals in the Supreme Court of the United States and courts of appeals around the country. Over the last 20+ years, Matt has argued five cases before the Supreme Court of the United States and participated in many more, including several high-profile triumphs over foreign sovereigns.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eA three-time \u0026ldquo;Litigator of the Week\u0026rdquo; \u003cem\u003e(The AmLaw Litigation Daily\u003c/em\u003e), Matt is consistently ranked by \u003cem\u003eChambers USA in Nationwide Appellate Law\u003c/em\u003e (2007-2025) and has been recognized by \u003cem\u003eThe National Law Journal\u003c/em\u003e as a 2020 \u0026ldquo;Litigation Trailblazer\u0026rdquo; for his pioneering work enforcing judgments against foreign sovereigns. Most recently, Matthew has been named to \u003cem\u003eLawdragon\u003c/em\u003e\u0026rsquo;s \u0026ldquo;500 Leading Litigators in America\u0026rdquo; guide (2024-2025) and was listed as a \u0026ldquo;Leading Global Litigator\u0026rdquo; for 2025.\u003c/p\u003e\n\u003cp\u003eAmong his many achievements, in 2020, Matthew successfully negotiated a $335 million resolution of terrorism claims against the Republic of Sudan arising from the 1998 bombings of the U.S. Embassies in Kenya and Tanzania. Previously, he successfully resolved NML Capital\u0026rsquo;s multi-billion dollar claims against the Republic of Argentina after what the \u003cem\u003eFinancial Times \u003c/em\u003ecalled \u0026ldquo;the trial of the century in sovereign debt restructuring.\u0026rdquo; His current case load includes public enforcement matters against the governments of Argentina, India, Iran, Spain, and Venezuela.\u003c/p\u003e\n\u003cp\u003eIn addition to his arbitral award enforcement and appellate practice, Matthew is highly regarded for his work at the intersection of sport and gaming. He is featured in the 2024 edition of \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e for Gaming Law and, for his work toward legalizing sports wagering and confining the Wire Act to its intended scope, Matthew has been recognized by \u003cem\u003eLaw360\u003c/em\u003e as a 2019 Sports Law \u0026ldquo;MVP\u0026rdquo; and \u0026ldquo;2020 Sports \u0026amp; Entertainment Trailblazer\u0026rdquo; by The \u003cem\u003eNational Law Journal\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003ePrior entering private practice, Matthew served as a Bristow Fellow in the Office of the Solicitor General at the U.S. Department of Justice. He clerked for the Hon. Joseph M. McLaughlin of the U.S. Court of Appeals for the Second Circuit and the Hon. John G. Roberts, Jr. of the U.S. Court of Appeals for the D.C. Circuit.\u003c/p\u003e","slug":"matthew-mcgill","email":"matthew.mcgill@kslaw.com ","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003e\u003cu\u003eInternational Disputes\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eSuccessfully negotiated a $335 million resolution of terrorism claims against the Republic of Sudan arising from the 1998 bombings of the U.S. Embassies in Kenya and Tanzania.\u003c/p\u003e","\u003cp\u003eSuccessfully resolved NML Capital\u0026rsquo;s multi-billion dollar claims against the Republic of Argentina after what the\u0026nbsp;\u003cem\u003eFinancial Times\u003c/em\u003e\u0026nbsp;called \u0026ldquo;the trial of the century in sovereign debt restructuring.\u003c/p\u003e","\u003cp\u003eObtained $1 billion judgment against the Islamic Republic of Iran for victims of the 2000 bombing of the U.S.S. Cole.\u003c/p\u003e","\u003cp\u003eLeading U.S. enforcement against the Kingdom of Spain of several arbitral awards redressing violations of the Energy Charter Treaty.\u003c/p\u003e","\u003cp\u003eLeading global enforcement of arbitral awards against the Government of India and the Republic of Argentina.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cu\u003eSupreme Court\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCC/Devas v. Antrix Corp.\u003c/em\u003e (2025) \u0026ndash; Arguing this case before the Supreme Court, Matt persuaded the Court to reject a lower court ruling that had found no jurisdiction to hear an enforcement action against one of India\u0026rsquo;s state-owed entities.\u0026nbsp; Matt\u0026rsquo;s 9-0 victory safeguarded the ability of arbitral award holders to bring enforcement actions in the United States against foreign sovereigns and their state-owned entities. \u0026nbsp;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOpati v. Republic of Sudan\u003c/em\u003e\u0026nbsp;(2020) \u0026ndash; Matt successfully argued before the Supreme Court on behalf of victims of the 1998 bombings of the U.S. Embassies in Kenya and Tanzania and secured a ruling that \u0026ldquo;unanimously reinstated as much as $4.3 billion in punitive damages awarded against Sudan\u0026rdquo; (\u003cem\u003eNew York Times\u003c/em\u003e) setting the stage for the resolution of the Embassy bombing claims and the United States\u0026rsquo; delisting of Sudan as a state-sponsor of terrorism.\u003c/p\u003e","\u003cp\u003e\u003cem\u003ePuerto Rico v. Franklin California Tax-Free Trust\u003c/em\u003e\u0026nbsp;(2016) \u0026ndash; Arguing before the Supreme Court on behalf of creditors that found themselves on the leading edge of Puerto Rico\u0026rsquo;s debt crisis, Matthew successfully defended an injunction invalidating Puerto Rico\u0026rsquo;s emergency municipal bankruptcy legislation. The ruling protected bondholders against the \u0026ldquo;chance that the territory could write its own bankruptcy plan\u0026rdquo; (\u003cem\u003eWall Street Journal\u003c/em\u003e) and ensured that Congress would retain control over Puerto Rico\u0026rsquo;s fiscal rescue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eBank Markazi v. Peterson\u003c/em\u003e\u0026nbsp;(2016) \u0026ndash; In this important separation-of-powers case, Matthew represented victims of the 1983 Beirut Marine Corps Barracks Bombing who hold judgments against Iran. Ruling in favor of the Beirut Marines, the Supreme Court rejected arguments from Iran\u0026rsquo;s central bank that Congress had impermissibly invaded the province of the Judicial Branch by authorizing victims of terrorism to seize certain central bank assets. The ruling allowed nearly $2 billion to be distributed to Iran\u0026rsquo;s victims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eArgentina v. NML Capital, Ltd.\u003c/em\u003e\u0026nbsp;(2014) \u0026ndash; The Supreme Court\u0026rsquo;s decision in this case confirmed the availability of broad discovery to enforce judgments against foreign sovereigns, empowering creditors to seek information concerning the debtor nation\u0026rsquo;s assets anywhere in the world.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cu\u003eSports and Gaming\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eLed the effort of the Governor of New Jersey to legalize sports wagering in the State, culminating in the Supreme Court\u0026rsquo;s \u0026ldquo;historic decision\u0026rdquo; (\u003cem\u003eSports Illustrated\u003c/em\u003e) in \u003cem\u003eMurphy v. NCAA\u003c/em\u003e that struck down the federal law that had prohibited states other than Nevada from legalizing sports betting. By establishing that the federal government has no power to \u0026ldquo;dictate what a state legislature may and may not do,\u0026rdquo; this \u0026ldquo;landmark ruling\u0026rdquo; (\u003cem\u003eUSA Today\u003c/em\u003e) safeguards the power of States to govern themselves and cleared the path for States across the country to legalize sports wagering.\u003c/p\u003e","\u003cp\u003eRepresented the technology provider for the internet-based operations of the New Hampshire Lottery, and secured a judgment that the Wire Act covered only sports betting, and successfully defended that judgment on appeal. The ruling safeguarded \u0026ldquo;the entire online gambling industry as well as multi-state lotteries such as Powerball\u0026rdquo; (\u003cem\u003eAm Law Litigation Daily\u003c/em\u003e) from an arbitrary change in government policy.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":14,"guid":"14.capabilities","index":1,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":2,"source":"capabilities"},{"id":38,"guid":"38.capabilities","index":3,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":4,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":5,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":6,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":7,"source":"capabilities"},{"id":131,"guid":"131.capabilities","index":8,"source":"capabilities"},{"id":1166,"guid":"1166.smart_tags","index":9,"source":"smartTags"},{"id":1,"guid":"1.smart_tags","index":10,"source":"smartTags"}],"is_active":true,"last_name":"McGill","nick_name":"Matt","clerkships":[{"name":"Law Clerk, Hon. John G. Roberts, Jr., U.S. Court of Appeals for the D.C. Circuit","years_held":"2003 - 2004"},{"name":"Law Clerk, Hon. Joseph M. McLaughlin, U.S. Court of Appeals for the Second Circuit","years_held":"2000 - 2002"}],"first_name":"Matthew","title_rank":9999,"updated_by":202,"law_schools":[{"id":1904,"meta":{"degree":"J.D.","honors":"Order of the Coif","is_law_school":"1","graduation_date":"2000-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"D.","name_suffix":"","recognitions":[{"title":"Ranked for Nationwide Appellate Law","detail":"Chambers \u0026 Partners, 2025"},{"title":"500 Leading Litigators in America","detail":"Lawdragon, 2025"},{"title":"Recognized for Work in Gaming Law","detail":"Best Lawyers in America, 2024"},{"title":"Litigation and Sports Trailblazer","detail":"The National Law Journal, 2020"},{"title":"Sports Law MVP","detail":"Law360, 2019"}],"linked_in_url":"https://www.linkedin.com/in/matthew-mcgill-7737564/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eMatthew D. McGill is a leader in arbitral award and judgment enforcement and an accomplished appellate advocate who handles civil litigation appeals in the Supreme Court of the United States and courts of appeals around the country. Over the last 20+ years, Matt has argued five cases before the Supreme Court of the United States and participated in many more, including several high-profile triumphs over foreign sovereigns.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eA three-time \u0026ldquo;Litigator of the Week\u0026rdquo; \u003cem\u003e(The AmLaw Litigation Daily\u003c/em\u003e), Matt is consistently ranked by \u003cem\u003eChambers USA in Nationwide Appellate Law\u003c/em\u003e (2007-2025) and has been recognized by \u003cem\u003eThe National Law Journal\u003c/em\u003e as a 2020 \u0026ldquo;Litigation Trailblazer\u0026rdquo; for his pioneering work enforcing judgments against foreign sovereigns. Most recently, Matthew has been named to \u003cem\u003eLawdragon\u003c/em\u003e\u0026rsquo;s \u0026ldquo;500 Leading Litigators in America\u0026rdquo; guide (2024-2025) and was listed as a \u0026ldquo;Leading Global Litigator\u0026rdquo; for 2025.\u003c/p\u003e\n\u003cp\u003eAmong his many achievements, in 2020, Matthew successfully negotiated a $335 million resolution of terrorism claims against the Republic of Sudan arising from the 1998 bombings of the U.S. Embassies in Kenya and Tanzania. Previously, he successfully resolved NML Capital\u0026rsquo;s multi-billion dollar claims against the Republic of Argentina after what the \u003cem\u003eFinancial Times \u003c/em\u003ecalled \u0026ldquo;the trial of the century in sovereign debt restructuring.\u0026rdquo; His current case load includes public enforcement matters against the governments of Argentina, India, Iran, Spain, and Venezuela.\u003c/p\u003e\n\u003cp\u003eIn addition to his arbitral award enforcement and appellate practice, Matthew is highly regarded for his work at the intersection of sport and gaming. He is featured in the 2024 edition of \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e for Gaming Law and, for his work toward legalizing sports wagering and confining the Wire Act to its intended scope, Matthew has been recognized by \u003cem\u003eLaw360\u003c/em\u003e as a 2019 Sports Law \u0026ldquo;MVP\u0026rdquo; and \u0026ldquo;2020 Sports \u0026amp; Entertainment Trailblazer\u0026rdquo; by The \u003cem\u003eNational Law Journal\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003ePrior entering private practice, Matthew served as a Bristow Fellow in the Office of the Solicitor General at the U.S. Department of Justice. He clerked for the Hon. Joseph M. McLaughlin of the U.S. Court of Appeals for the Second Circuit and the Hon. John G. Roberts, Jr. of the U.S. Court of Appeals for the D.C. Circuit.\u003c/p\u003e","matters":["\u003cp\u003e\u003cstrong\u003e\u003cu\u003eInternational Disputes\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eSuccessfully negotiated a $335 million resolution of terrorism claims against the Republic of Sudan arising from the 1998 bombings of the U.S. Embassies in Kenya and Tanzania.\u003c/p\u003e","\u003cp\u003eSuccessfully resolved NML Capital\u0026rsquo;s multi-billion dollar claims against the Republic of Argentina after what the\u0026nbsp;\u003cem\u003eFinancial Times\u003c/em\u003e\u0026nbsp;called \u0026ldquo;the trial of the century in sovereign debt restructuring.\u003c/p\u003e","\u003cp\u003eObtained $1 billion judgment against the Islamic Republic of Iran for victims of the 2000 bombing of the U.S.S. Cole.\u003c/p\u003e","\u003cp\u003eLeading U.S. enforcement against the Kingdom of Spain of several arbitral awards redressing violations of the Energy Charter Treaty.\u003c/p\u003e","\u003cp\u003eLeading global enforcement of arbitral awards against the Government of India and the Republic of Argentina.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cu\u003eSupreme Court\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCC/Devas v. Antrix Corp.\u003c/em\u003e (2025) \u0026ndash; Arguing this case before the Supreme Court, Matt persuaded the Court to reject a lower court ruling that had found no jurisdiction to hear an enforcement action against one of India\u0026rsquo;s state-owed entities.\u0026nbsp; Matt\u0026rsquo;s 9-0 victory safeguarded the ability of arbitral award holders to bring enforcement actions in the United States against foreign sovereigns and their state-owned entities. \u0026nbsp;\u003c/p\u003e","\u003cp\u003e\u003cem\u003eOpati v. Republic of Sudan\u003c/em\u003e\u0026nbsp;(2020) \u0026ndash; Matt successfully argued before the Supreme Court on behalf of victims of the 1998 bombings of the U.S. Embassies in Kenya and Tanzania and secured a ruling that \u0026ldquo;unanimously reinstated as much as $4.3 billion in punitive damages awarded against Sudan\u0026rdquo; (\u003cem\u003eNew York Times\u003c/em\u003e) setting the stage for the resolution of the Embassy bombing claims and the United States\u0026rsquo; delisting of Sudan as a state-sponsor of terrorism.\u003c/p\u003e","\u003cp\u003e\u003cem\u003ePuerto Rico v. Franklin California Tax-Free Trust\u003c/em\u003e\u0026nbsp;(2016) \u0026ndash; Arguing before the Supreme Court on behalf of creditors that found themselves on the leading edge of Puerto Rico\u0026rsquo;s debt crisis, Matthew successfully defended an injunction invalidating Puerto Rico\u0026rsquo;s emergency municipal bankruptcy legislation. The ruling protected bondholders against the \u0026ldquo;chance that the territory could write its own bankruptcy plan\u0026rdquo; (\u003cem\u003eWall Street Journal\u003c/em\u003e) and ensured that Congress would retain control over Puerto Rico\u0026rsquo;s fiscal rescue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eBank Markazi v. Peterson\u003c/em\u003e\u0026nbsp;(2016) \u0026ndash; In this important separation-of-powers case, Matthew represented victims of the 1983 Beirut Marine Corps Barracks Bombing who hold judgments against Iran. Ruling in favor of the Beirut Marines, the Supreme Court rejected arguments from Iran\u0026rsquo;s central bank that Congress had impermissibly invaded the province of the Judicial Branch by authorizing victims of terrorism to seize certain central bank assets. The ruling allowed nearly $2 billion to be distributed to Iran\u0026rsquo;s victims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eArgentina v. NML Capital, Ltd.\u003c/em\u003e\u0026nbsp;(2014) \u0026ndash; The Supreme Court\u0026rsquo;s decision in this case confirmed the availability of broad discovery to enforce judgments against foreign sovereigns, empowering creditors to seek information concerning the debtor nation\u0026rsquo;s assets anywhere in the world.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003e\u003cu\u003eSports and Gaming\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eLed the effort of the Governor of New Jersey to legalize sports wagering in the State, culminating in the Supreme Court\u0026rsquo;s \u0026ldquo;historic decision\u0026rdquo; (\u003cem\u003eSports Illustrated\u003c/em\u003e) in \u003cem\u003eMurphy v. NCAA\u003c/em\u003e that struck down the federal law that had prohibited states other than Nevada from legalizing sports betting. By establishing that the federal government has no power to \u0026ldquo;dictate what a state legislature may and may not do,\u0026rdquo; this \u0026ldquo;landmark ruling\u0026rdquo; (\u003cem\u003eUSA Today\u003c/em\u003e) safeguards the power of States to govern themselves and cleared the path for States across the country to legalize sports wagering.\u003c/p\u003e","\u003cp\u003eRepresented the technology provider for the internet-based operations of the New Hampshire Lottery, and secured a judgment that the Wire Act covered only sports betting, and successfully defended that judgment on appeal. The ruling safeguarded \u0026ldquo;the entire online gambling industry as well as multi-state lotteries such as Powerball\u0026rdquo; (\u003cem\u003eAm Law Litigation Daily\u003c/em\u003e) from an arbitrary change in government policy.\u003c/p\u003e"],"recognitions":[{"title":"Ranked for Nationwide Appellate Law","detail":"Chambers \u0026 Partners, 2025"},{"title":"500 Leading Litigators in America","detail":"Lawdragon, 2025"},{"title":"Recognized for Work in Gaming Law","detail":"Best Lawyers in America, 2024"},{"title":"Litigation and Sports Trailblazer","detail":"The National Law Journal, 2020"},{"title":"Sports Law MVP","detail":"Law360, 2019"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12931}]},"capability_group_id":3},"created_at":"2025-09-11T18:32:36.000Z","updated_at":"2025-09-11T18:32:36.000Z","searchable_text":"McGill{{ FIELD }}{:title=\u0026gt;\"Ranked for Nationwide Appellate Law\", :detail=\u0026gt;\"Chambers \u0026amp; Partners, 2025\"}{{ FIELD }}{:title=\u0026gt;\"500 Leading Litigators in America\", :detail=\u0026gt;\"Lawdragon, 2025\"}{{ FIELD }}{:title=\u0026gt;\"Recognized for Work in Gaming Law\", :detail=\u0026gt;\"Best Lawyers in America, 2024\"}{{ FIELD }}{:title=\u0026gt;\"Litigation and Sports Trailblazer\", :detail=\u0026gt;\"The National Law Journal, 2020\"}{{ FIELD }}{:title=\u0026gt;\"Sports Law MVP\", :detail=\u0026gt;\"Law360, 2019\"}{{ FIELD }}International Disputes{{ FIELD }}Successfully negotiated a $335 million resolution of terrorism claims against the Republic of Sudan arising from the 1998 bombings of the U.S. Embassies in Kenya and Tanzania.{{ FIELD }}Successfully resolved NML Capital’s multi-billion dollar claims against the Republic of Argentina after what the Financial Times called “the trial of the century in sovereign debt restructuring.{{ FIELD }}Obtained $1 billion judgment against the Islamic Republic of Iran for victims of the 2000 bombing of the U.S.S. Cole.{{ FIELD }}Leading U.S. enforcement against the Kingdom of Spain of several arbitral awards redressing violations of the Energy Charter Treaty.{{ FIELD }}Leading global enforcement of arbitral awards against the Government of India and the Republic of Argentina.{{ FIELD }}Supreme Court{{ FIELD }}CC/Devas v. Antrix Corp. (2025) – Arguing this case before the Supreme Court, Matt persuaded the Court to reject a lower court ruling that had found no jurisdiction to hear an enforcement action against one of India’s state-owed entities.  Matt’s 9-0 victory safeguarded the ability of arbitral award holders to bring enforcement actions in the United States against foreign sovereigns and their state-owned entities.  {{ FIELD }}Opati v. Republic of Sudan (2020) – Matt successfully argued before the Supreme Court on behalf of victims of the 1998 bombings of the U.S. Embassies in Kenya and Tanzania and secured a ruling that “unanimously reinstated as much as $4.3 billion in punitive damages awarded against Sudan” (New York Times) setting the stage for the resolution of the Embassy bombing claims and the United States’ delisting of Sudan as a state-sponsor of terrorism.{{ FIELD }}Puerto Rico v. Franklin California Tax-Free Trust (2016) – Arguing before the Supreme Court on behalf of creditors that found themselves on the leading edge of Puerto Rico’s debt crisis, Matthew successfully defended an injunction invalidating Puerto Rico’s emergency municipal bankruptcy legislation. The ruling protected bondholders against the “chance that the territory could write its own bankruptcy plan” (Wall Street Journal) and ensured that Congress would retain control over Puerto Rico’s fiscal rescue.{{ FIELD }}Bank Markazi v. Peterson (2016) – In this important separation-of-powers case, Matthew represented victims of the 1983 Beirut Marine Corps Barracks Bombing who hold judgments against Iran. Ruling in favor of the Beirut Marines, the Supreme Court rejected arguments from Iran’s central bank that Congress had impermissibly invaded the province of the Judicial Branch by authorizing victims of terrorism to seize certain central bank assets. The ruling allowed nearly $2 billion to be distributed to Iran’s victims.{{ FIELD }}Argentina v. NML Capital, Ltd. (2014) – The Supreme Court’s decision in this case confirmed the availability of broad discovery to enforce judgments against foreign sovereigns, empowering creditors to seek information concerning the debtor nation’s assets anywhere in the world.{{ FIELD }}Sports and Gaming{{ FIELD }}Led the effort of the Governor of New Jersey to legalize sports wagering in the State, culminating in the Supreme Court’s “historic decision” (Sports Illustrated) in Murphy v. NCAA that struck down the federal law that had prohibited states other than Nevada from legalizing sports betting. By establishing that the federal government has no power to “dictate what a state legislature may and may not do,” this “landmark ruling” (USA Today) safeguards the power of States to govern themselves and cleared the path for States across the country to legalize sports wagering.{{ FIELD }}Represented the technology provider for the internet-based operations of the New Hampshire Lottery, and secured a judgment that the Wire Act covered only sports betting, and successfully defended that judgment on appeal. The ruling safeguarded “the entire online gambling industry as well as multi-state lotteries such as Powerball” (Am Law Litigation Daily) from an arbitrary change in government policy.{{ FIELD }}Matthew D. McGill is a leader in arbitral award and judgment enforcement and an accomplished appellate advocate who handles civil litigation appeals in the Supreme Court of the United States and courts of appeals around the country. Over the last 20+ years, Matt has argued five cases before the Supreme Court of the United States and participated in many more, including several high-profile triumphs over foreign sovereigns.\nA three-time “Litigator of the Week” (The AmLaw Litigation Daily), Matt is consistently ranked by Chambers USA in Nationwide Appellate Law (2007-2025) and has been recognized by The National Law Journal as a 2020 “Litigation Trailblazer” for his pioneering work enforcing judgments against foreign sovereigns. Most recently, Matthew has been named to Lawdragon’s “500 Leading Litigators in America” guide (2024-2025) and was listed as a “Leading Global Litigator” for 2025.\nAmong his many achievements, in 2020, Matthew successfully negotiated a $335 million resolution of terrorism claims against the Republic of Sudan arising from the 1998 bombings of the U.S. Embassies in Kenya and Tanzania. Previously, he successfully resolved NML Capital’s multi-billion dollar claims against the Republic of Argentina after what the Financial Times called “the trial of the century in sovereign debt restructuring.” His current case load includes public enforcement matters against the governments of Argentina, India, Iran, Spain, and Venezuela.\nIn addition to his arbitral award enforcement and appellate practice, Matthew is highly regarded for his work at the intersection of sport and gaming. He is featured in the 2024 edition of The Best Lawyers in America for Gaming Law and, for his work toward legalizing sports wagering and confining the Wire Act to its intended scope, Matthew has been recognized by Law360 as a 2019 Sports Law “MVP” and “2020 Sports \u0026amp; Entertainment Trailblazer” by The National Law Journal.\nPrior entering private practice, Matthew served as a Bristow Fellow in the Office of the Solicitor General at the U.S. Department of Justice. He clerked for the Hon. Joseph M. McLaughlin of the U.S. Court of Appeals for the Second Circuit and the Hon. John G. Roberts, Jr. of the U.S. Court of Appeals for the D.C. Circuit. Partner Ranked for Nationwide Appellate Law Chambers \u0026amp; Partners, 2025 500 Leading Litigators in America Lawdragon, 2025 Recognized for Work in Gaming Law Best Lawyers in America, 2024 Litigation and Sports Trailblazer The National Law Journal, 2020 Sports Law MVP Law360, 2019 Dartmouth College  Stanford University Stanford Law School District of Columbia New York Law Clerk, Hon. John G. Roberts, Jr., U.S. Court of Appeals for the D.C. Circuit Law Clerk, Hon. Joseph M. McLaughlin, U.S. Court of Appeals for the Second Circuit International Disputes Successfully negotiated a $335 million resolution of terrorism claims against the Republic of Sudan arising from the 1998 bombings of the U.S. Embassies in Kenya and Tanzania. Successfully resolved NML Capital’s multi-billion dollar claims against the Republic of Argentina after what the Financial Times called “the trial of the century in sovereign debt restructuring. Obtained $1 billion judgment against the Islamic Republic of Iran for victims of the 2000 bombing of the U.S.S. Cole. Leading U.S. enforcement against the Kingdom of Spain of several arbitral awards redressing violations of the Energy Charter Treaty. Leading global enforcement of arbitral awards against the Government of India and the Republic of Argentina. Supreme Court CC/Devas v. Antrix Corp. (2025) – Arguing this case before the Supreme Court, Matt persuaded the Court to reject a lower court ruling that had found no jurisdiction to hear an enforcement action against one of India’s state-owed entities.  Matt’s 9-0 victory safeguarded the ability of arbitral award holders to bring enforcement actions in the United States against foreign sovereigns and their state-owned entities.   Opati v. Republic of Sudan (2020) – Matt successfully argued before the Supreme Court on behalf of victims of the 1998 bombings of the U.S. Embassies in Kenya and Tanzania and secured a ruling that “unanimously reinstated as much as $4.3 billion in punitive damages awarded against Sudan” (New York Times) setting the stage for the resolution of the Embassy bombing claims and the United States’ delisting of Sudan as a state-sponsor of terrorism. Puerto Rico v. Franklin California Tax-Free Trust (2016) – Arguing before the Supreme Court on behalf of creditors that found themselves on the leading edge of Puerto Rico’s debt crisis, Matthew successfully defended an injunction invalidating Puerto Rico’s emergency municipal bankruptcy legislation. The ruling protected bondholders against the “chance that the territory could write its own bankruptcy plan” (Wall Street Journal) and ensured that Congress would retain control over Puerto Rico’s fiscal rescue. Bank Markazi v. Peterson (2016) – In this important separation-of-powers case, Matthew represented victims of the 1983 Beirut Marine Corps Barracks Bombing who hold judgments against Iran. Ruling in favor of the Beirut Marines, the Supreme Court rejected arguments from Iran’s central bank that Congress had impermissibly invaded the province of the Judicial Branch by authorizing victims of terrorism to seize certain central bank assets. The ruling allowed nearly $2 billion to be distributed to Iran’s victims. Argentina v. NML Capital, Ltd. (2014) – The Supreme Court’s decision in this case confirmed the availability of broad discovery to enforce judgments against foreign sovereigns, empowering creditors to seek information concerning the debtor nation’s assets anywhere in the world. Sports and Gaming Led the effort of the Governor of New Jersey to legalize sports wagering in the State, culminating in the Supreme Court’s “historic decision” (Sports Illustrated) in Murphy v. NCAA that struck down the federal law that had prohibited states other than Nevada from legalizing sports betting. By establishing that the federal government has no power to “dictate what a state legislature may and may not do,” this “landmark ruling” (USA Today) safeguards the power of States to govern themselves and cleared the path for States across the country to legalize sports wagering. Represented the technology provider for the internet-based operations of the New Hampshire Lottery, and secured a judgment that the Wire Act covered only sports betting, and successfully defended that judgment on appeal. The ruling safeguarded “the entire online gambling industry as well as multi-state lotteries such as Powerball” (Am Law Litigation Daily) from an arbitrary change in government policy.","searchable_name":"Matthew D. McGill (Matt)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426677,"version":1,"owner_type":"Person","owner_id":5427,"payload":{"bio":"\u003cp\u003eDerek Meilman is the lawyer of choice for complex transatlantic mergers, acquisitions and strategic joint ventures which require a nuanced engagement with government bodies and state actors, whether as regulators, investors, sponsors, legislators or otherwise. Qualified as an attorney in New York State and as a solicitor in England \u0026amp; Wales and the Republic of Ireland, Derek\u0026rsquo;s clients include major multinational companies, private equity groups, governments (including sovereign wealth funds and multilateral organizations) and family offices.\u0026nbsp;Derek has a BA from Brown University and a JD from the Duke University School of Law. In addition to his law practice, Derek serves as a non-executive director on the board of CA Ron Santa Teresa, the Caracas stock exchange-listed producer of the award-winning \u0026lsquo;Santa Teresa 1796\u0026rsquo; solera method rum.\u003c/p\u003e","slug":"derek-meilman","email":"dmeilman@kslaw.com","phone":"+44 759 000 3654","matters":["\u003cp\u003eRepresented Francisco Partners portfolio company Keyloop in connection with its acquisition of 100% of the shares of Automotive Transformation Group from Inflexion Private Equity\u003c/p\u003e","\u003cp\u003eRepresented the Aydin Group of Turkiye (the owner of A101, English Home, Eve and Memorial Healthcare Group) on the sale to the Dubai Islamic Bank of a minority stake in the T.O.M. Group, a digital banking and financial technology business\u003c/p\u003e","\u003cp\u003eRepresented Afendis Capital Management in connection with the acquisition by Afendis and Davidson Kempner Capital Management of 100% of Gelato d\u0026rsquo;Italia, the leading independent ice-cream producer in Italy\u003c/p\u003e","\u003cp\u003eRepresented Afendis Capital Management in connection with the acquisition, in the context of a complex restructuring, by Afendis and Davidson Kempner Capital Management of a controlling interest in Cerealto Siro Foods, a Spanish co-manufacturer and private-label producer of cookies, cereals and pasta\u003c/p\u003e","\u003cp\u003eRepresented Afendis Capital Partners as transaction sponsor in connection with the acquisition by a private equity consortium, including Afendis and Metric Capital Partners, of a 30% stake in Turkish generic drug maker Sanovel\u003c/p\u003e","\u003cp\u003eRepresented Olivier Creed in the sale of Creed fragrances, one of the world\u0026rsquo;s leading luxury perfume houses, to BlackRock Long Term Private Capital, a perpetual capital private equity fund within the world\u0026rsquo;s largest asset manager, and Javier Ferr\u0026aacute;n, Chairman of Diageo\u003c/p\u003e","\u003cp\u003eRepresented Ron Santa Teresa of Venezuela in connection with an international distribution alliance with Bacardi, the world's largest privately owned spirits company\u003c/p\u003e","\u003cp\u003eRepresented WSP Global in connection with the acquisition for US$1.31bn of Parsons Brinckerhoff from infrastructure group Balfour Beatty\u003c/p\u003e","\u003cp\u003eRepresented the senior noteholders of Ukrainian agricultural company Mriya in the restructuring which resulted in ownership of the company by its former creditors and then the onward sale of the Mriya business to the Saudi Agricultural \u0026amp; Livestock Investment Company\u003c/p\u003e","\u003cp\u003eRepresented Global Solar Energy, a manufacturer of flexible solar technology, on its sale to the Hanergy Group of China\u003c/p\u003e","\u003cp\u003eRepresented Colombian financial services firm Grupo Sura in connection with its buyout of JP Morgan, General Atlantic and IFC interests in Sura Asset Management\u003c/p\u003e","\u003cp\u003eRepresented NorthStar Realty Europe and China Resources Land on acquisition from AXA Investment Managers of 20 Gresham St., a trophy office building in the City of London\u003c/p\u003e","\u003cp\u003eRepresented Colony Capital in connection with the acquisition of an interest in the Fibonacci Square development project in Ballsbridge, Dublin and related arrangements among partners\u003c/p\u003e","\u003cp\u003eRepresented Metsanco Ltd and its affiliates in the sale of Olo de Peru and TVS Wireless to a subsidiary of America Movil, the Mexican telecom\u003c/p\u003e","\u003cp\u003eRepresented LeapFrog Investments, which invests in businesses in Africa and Asia, in connection with multiple M\u0026amp;A transactions\u003c/p\u003e","\u003cp\u003eRepresented Kodak Pension Plan (KPP) in connection with its acquisition of Kodak Alaris in settlement of KPP's claim in the Eastman Kodak bankruptcy\u003c/p\u003e","\u003cp\u003eRepresented Quantum Pacific Exploration in connection with a strategic partnership with Barrick Gold to explore for and develop copper deposits in Chile\u003c/p\u003e","\u003cp\u003eRepresented The Gores Group in its acquisition of a majority stake in Mexx International from Liz Claiborne, including the formation of a related joint venture\u003c/p\u003e","\u003cp\u003eRepresented marine transportation services company American Commercial Lines in connection with its US$800m \u0026lsquo;going private\u0026rsquo; sale to Platinum Equity\u003c/p\u003e","\u003cp\u003eRepresented an American subsidiary of a European aerospace and defense company in its disposition of an entity under a proxy agreement with the US Department of Defense\u003c/p\u003e","\u003cp\u003eRepresented NBCUniversal in connection with its sale of Los Angeles-based Spanish-language television station KWHY-TV to Meruelo Enterprises\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":75,"guid":"75.capabilities","index":0,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":1,"source":"capabilities"},{"id":33,"guid":"33.capabilities","index":2,"source":"capabilities"},{"id":27,"guid":"27.capabilities","index":3,"source":"capabilities"},{"id":80,"guid":"80.capabilities","index":4,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":5,"source":"capabilities"},{"id":110,"guid":"110.capabilities","index":6,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":7,"source":"capabilities"},{"id":105,"guid":"105.capabilities","index":8,"source":"capabilities"},{"id":104,"guid":"104.capabilities","index":9,"source":"capabilities"},{"id":126,"guid":"126.capabilities","index":10,"source":"capabilities"},{"id":1220,"guid":"1220.smart_tags","index":11,"source":"smartTags"},{"id":128,"guid":"128.capabilities","index":12,"source":"capabilities"},{"id":1261,"guid":"1261.smart_tags","index":13,"source":"smartTags"}],"is_active":true,"last_name":"Meilman","nick_name":"Derek","clerkships":[],"first_name":"Derek","title_rank":9999,"updated_by":35,"law_schools":[{"id":613,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"2002-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":"","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eDerek Meilman is the lawyer of choice for complex transatlantic mergers, acquisitions and strategic joint ventures which require a nuanced engagement with government bodies and state actors, whether as regulators, investors, sponsors, legislators or otherwise. Qualified as an attorney in New York State and as a solicitor in England \u0026amp; Wales and the Republic of Ireland, Derek\u0026rsquo;s clients include major multinational companies, private equity groups, governments (including sovereign wealth funds and multilateral organizations) and family offices.\u0026nbsp;Derek has a BA from Brown University and a JD from the Duke University School of Law. In addition to his law practice, Derek serves as a non-executive director on the board of CA Ron Santa Teresa, the Caracas stock exchange-listed producer of the award-winning \u0026lsquo;Santa Teresa 1796\u0026rsquo; solera method rum.\u003c/p\u003e","matters":["\u003cp\u003eRepresented Francisco Partners portfolio company Keyloop in connection with its acquisition of 100% of the shares of Automotive Transformation Group from Inflexion Private Equity\u003c/p\u003e","\u003cp\u003eRepresented the Aydin Group of Turkiye (the owner of A101, English Home, Eve and Memorial Healthcare Group) on the sale to the Dubai Islamic Bank of a minority stake in the T.O.M. Group, a digital banking and financial technology business\u003c/p\u003e","\u003cp\u003eRepresented Afendis Capital Management in connection with the acquisition by Afendis and Davidson Kempner Capital Management of 100% of Gelato d\u0026rsquo;Italia, the leading independent ice-cream producer in Italy\u003c/p\u003e","\u003cp\u003eRepresented Afendis Capital Management in connection with the acquisition, in the context of a complex restructuring, by Afendis and Davidson Kempner Capital Management of a controlling interest in Cerealto Siro Foods, a Spanish co-manufacturer and private-label producer of cookies, cereals and pasta\u003c/p\u003e","\u003cp\u003eRepresented Afendis Capital Partners as transaction sponsor in connection with the acquisition by a private equity consortium, including Afendis and Metric Capital Partners, of a 30% stake in Turkish generic drug maker Sanovel\u003c/p\u003e","\u003cp\u003eRepresented Olivier Creed in the sale of Creed fragrances, one of the world\u0026rsquo;s leading luxury perfume houses, to BlackRock Long Term Private Capital, a perpetual capital private equity fund within the world\u0026rsquo;s largest asset manager, and Javier Ferr\u0026aacute;n, Chairman of Diageo\u003c/p\u003e","\u003cp\u003eRepresented Ron Santa Teresa of Venezuela in connection with an international distribution alliance with Bacardi, the world's largest privately owned spirits company\u003c/p\u003e","\u003cp\u003eRepresented WSP Global in connection with the acquisition for US$1.31bn of Parsons Brinckerhoff from infrastructure group Balfour Beatty\u003c/p\u003e","\u003cp\u003eRepresented the senior noteholders of Ukrainian agricultural company Mriya in the restructuring which resulted in ownership of the company by its former creditors and then the onward sale of the Mriya business to the Saudi Agricultural \u0026amp; Livestock Investment Company\u003c/p\u003e","\u003cp\u003eRepresented Global Solar Energy, a manufacturer of flexible solar technology, on its sale to the Hanergy Group of China\u003c/p\u003e","\u003cp\u003eRepresented Colombian financial services firm Grupo Sura in connection with its buyout of JP Morgan, General Atlantic and IFC interests in Sura Asset Management\u003c/p\u003e","\u003cp\u003eRepresented NorthStar Realty Europe and China Resources Land on acquisition from AXA Investment Managers of 20 Gresham St., a trophy office building in the City of London\u003c/p\u003e","\u003cp\u003eRepresented Colony Capital in connection with the acquisition of an interest in the Fibonacci Square development project in Ballsbridge, Dublin and related arrangements among partners\u003c/p\u003e","\u003cp\u003eRepresented Metsanco Ltd and its affiliates in the sale of Olo de Peru and TVS Wireless to a subsidiary of America Movil, the Mexican telecom\u003c/p\u003e","\u003cp\u003eRepresented LeapFrog Investments, which invests in businesses in Africa and Asia, in connection with multiple M\u0026amp;A transactions\u003c/p\u003e","\u003cp\u003eRepresented Kodak Pension Plan (KPP) in connection with its acquisition of Kodak Alaris in settlement of KPP's claim in the Eastman Kodak bankruptcy\u003c/p\u003e","\u003cp\u003eRepresented Quantum Pacific Exploration in connection with a strategic partnership with Barrick Gold to explore for and develop copper deposits in Chile\u003c/p\u003e","\u003cp\u003eRepresented The Gores Group in its acquisition of a majority stake in Mexx International from Liz Claiborne, including the formation of a related joint venture\u003c/p\u003e","\u003cp\u003eRepresented marine transportation services company American Commercial Lines in connection with its US$800m \u0026lsquo;going private\u0026rsquo; sale to Platinum Equity\u003c/p\u003e","\u003cp\u003eRepresented an American subsidiary of a European aerospace and defense company in its disposition of an entity under a proxy agreement with the US Department of Defense\u003c/p\u003e","\u003cp\u003eRepresented NBCUniversal in connection with its sale of Los Angeles-based Spanish-language television station KWHY-TV to Meruelo Enterprises\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":9172}]},"capability_group_id":1},"created_at":"2025-05-26T04:55:56.000Z","updated_at":"2025-05-26T04:55:56.000Z","searchable_text":"Meilman{{ FIELD }}Represented Francisco Partners portfolio company Keyloop in connection with its acquisition of 100% of the shares of Automotive Transformation Group from Inflexion Private Equity{{ FIELD }}Represented the Aydin Group of Turkiye (the owner of A101, English Home, Eve and Memorial Healthcare Group) on the sale to the Dubai Islamic Bank of a minority stake in the T.O.M. Group, a digital banking and financial technology business{{ FIELD }}Represented Afendis Capital Management in connection with the acquisition by Afendis and Davidson Kempner Capital Management of 100% of Gelato d’Italia, the leading independent ice-cream producer in Italy{{ FIELD }}Represented Afendis Capital Management in connection with the acquisition, in the context of a complex restructuring, by Afendis and Davidson Kempner Capital Management of a controlling interest in Cerealto Siro Foods, a Spanish co-manufacturer and private-label producer of cookies, cereals and pasta{{ FIELD }}Represented Afendis Capital Partners as transaction sponsor in connection with the acquisition by a private equity consortium, including Afendis and Metric Capital Partners, of a 30% stake in Turkish generic drug maker Sanovel{{ FIELD }}Represented Olivier Creed in the sale of Creed fragrances, one of the world’s leading luxury perfume houses, to BlackRock Long Term Private Capital, a perpetual capital private equity fund within the world’s largest asset manager, and Javier Ferrán, Chairman of Diageo{{ FIELD }}Represented Ron Santa Teresa of Venezuela in connection with an international distribution alliance with Bacardi, the world's largest privately owned spirits company{{ FIELD }}Represented WSP Global in connection with the acquisition for US$1.31bn of Parsons Brinckerhoff from infrastructure group Balfour Beatty{{ FIELD }}Represented the senior noteholders of Ukrainian agricultural company Mriya in the restructuring which resulted in ownership of the company by its former creditors and then the onward sale of the Mriya business to the Saudi Agricultural \u0026amp; Livestock Investment Company{{ FIELD }}Represented Global Solar Energy, a manufacturer of flexible solar technology, on its sale to the Hanergy Group of China{{ FIELD }}Represented Colombian financial services firm Grupo Sura in connection with its buyout of JP Morgan, General Atlantic and IFC interests in Sura Asset Management{{ FIELD }}Represented NorthStar Realty Europe and China Resources Land on acquisition from AXA Investment Managers of 20 Gresham St., a trophy office building in the City of London{{ FIELD }}Represented Colony Capital in connection with the acquisition of an interest in the Fibonacci Square development project in Ballsbridge, Dublin and related arrangements among partners{{ FIELD }}Represented Metsanco Ltd and its affiliates in the sale of Olo de Peru and TVS Wireless to a subsidiary of America Movil, the Mexican telecom{{ FIELD }}Represented LeapFrog Investments, which invests in businesses in Africa and Asia, in connection with multiple M\u0026amp;A transactions{{ FIELD }}Represented Kodak Pension Plan (KPP) in connection with its acquisition of Kodak Alaris in settlement of KPP's claim in the Eastman Kodak bankruptcy{{ FIELD }}Represented Quantum Pacific Exploration in connection with a strategic partnership with Barrick Gold to explore for and develop copper deposits in Chile{{ FIELD }}Represented The Gores Group in its acquisition of a majority stake in Mexx International from Liz Claiborne, including the formation of a related joint venture{{ FIELD }}Represented marine transportation services company American Commercial Lines in connection with its US$800m ‘going private’ sale to Platinum Equity{{ FIELD }}Represented an American subsidiary of a European aerospace and defense company in its disposition of an entity under a proxy agreement with the US Department of Defense{{ FIELD }}Represented NBCUniversal in connection with its sale of Los Angeles-based Spanish-language television station KWHY-TV to Meruelo Enterprises{{ FIELD }}Derek Meilman is the lawyer of choice for complex transatlantic mergers, acquisitions and strategic joint ventures which require a nuanced engagement with government bodies and state actors, whether as regulators, investors, sponsors, legislators or otherwise. Qualified as an attorney in New York State and as a solicitor in England \u0026amp; Wales and the Republic of Ireland, Derek’s clients include major multinational companies, private equity groups, governments (including sovereign wealth funds and multilateral organizations) and family offices. Derek has a BA from Brown University and a JD from the Duke University School of Law. In addition to his law practice, Derek serves as a non-executive director on the board of CA Ron Santa Teresa, the Caracas stock exchange-listed producer of the award-winning ‘Santa Teresa 1796’ solera method rum. Partner Brown University  Financial Times  Duke University Duke University School of Law New York England and Wales Ireland Represented Francisco Partners portfolio company Keyloop in connection with its acquisition of 100% of the shares of Automotive Transformation Group from Inflexion Private Equity Represented the Aydin Group of Turkiye (the owner of A101, English Home, Eve and Memorial Healthcare Group) on the sale to the Dubai Islamic Bank of a minority stake in the T.O.M. Group, a digital banking and financial technology business Represented Afendis Capital Management in connection with the acquisition by Afendis and Davidson Kempner Capital Management of 100% of Gelato d’Italia, the leading independent ice-cream producer in Italy Represented Afendis Capital Management in connection with the acquisition, in the context of a complex restructuring, by Afendis and Davidson Kempner Capital Management of a controlling interest in Cerealto Siro Foods, a Spanish co-manufacturer and private-label producer of cookies, cereals and pasta Represented Afendis Capital Partners as transaction sponsor in connection with the acquisition by a private equity consortium, including Afendis and Metric Capital Partners, of a 30% stake in Turkish generic drug maker Sanovel Represented Olivier Creed in the sale of Creed fragrances, one of the world’s leading luxury perfume houses, to BlackRock Long Term Private Capital, a perpetual capital private equity fund within the world’s largest asset manager, and Javier Ferrán, Chairman of Diageo Represented Ron Santa Teresa of Venezuela in connection with an international distribution alliance with Bacardi, the world's largest privately owned spirits company Represented WSP Global in connection with the acquisition for US$1.31bn of Parsons Brinckerhoff from infrastructure group Balfour Beatty Represented the senior noteholders of Ukrainian agricultural company Mriya in the restructuring which resulted in ownership of the company by its former creditors and then the onward sale of the Mriya business to the Saudi Agricultural \u0026amp; Livestock Investment Company Represented Global Solar Energy, a manufacturer of flexible solar technology, on its sale to the Hanergy Group of China Represented Colombian financial services firm Grupo Sura in connection with its buyout of JP Morgan, General Atlantic and IFC interests in Sura Asset Management Represented NorthStar Realty Europe and China Resources Land on acquisition from AXA Investment Managers of 20 Gresham St., a trophy office building in the City of London Represented Colony Capital in connection with the acquisition of an interest in the Fibonacci Square development project in Ballsbridge, Dublin and related arrangements among partners Represented Metsanco Ltd and its affiliates in the sale of Olo de Peru and TVS Wireless to a subsidiary of America Movil, the Mexican telecom Represented LeapFrog Investments, which invests in businesses in Africa and Asia, in connection with multiple M\u0026amp;A transactions Represented Kodak Pension Plan (KPP) in connection with its acquisition of Kodak Alaris in settlement of KPP's claim in the Eastman Kodak bankruptcy Represented Quantum Pacific Exploration in connection with a strategic partnership with Barrick Gold to explore for and develop copper deposits in Chile Represented The Gores Group in its acquisition of a majority stake in Mexx International from Liz Claiborne, including the formation of a related joint venture Represented marine transportation services company American Commercial Lines in connection with its US$800m ‘going private’ sale to Platinum Equity Represented an American subsidiary of a European aerospace and defense company in its disposition of an entity under a proxy agreement with the US Department of Defense Represented NBCUniversal in connection with its sale of Los Angeles-based Spanish-language television station KWHY-TV to Meruelo Enterprises","searchable_name":"Derek Meilman","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null},{"id":426536,"version":1,"owner_type":"Person","owner_id":4090,"payload":{"bio":"\u003cp\u003eGary Messplay specializes in advising life science companies on regulatory, compliance and transactional matters. A partner in our nationally recognized FDA and Life Sciences practice, Gary has almost 30 years of experience representing large multinational pharmaceutical and medical-device companies, as well as emerging companies.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGary advices clients in matters relating to the approval and commercialization of products that are regulated by the Food\u0026nbsp;and Drug Administration and other federal and state agencies.\u0026nbsp; Gary has substantial experience advising clients on all aspects of product approvals; product launches and commercialization including advertising and promotion; leading compliance-related investigations; developing and implementing regulatory and healthcare compliance programs; advising on patient support programs; and managing competitor disputes.\u0026nbsp; In addition, Gary regularly advises clients on matters relating to healthcare fraud and abuse, clinical trials, informed consent, drug safety issues, product liability, recalls, responding to 483s, warning letters and complete response letters, drug and device quality and manufacturing issues, and life cycle management.\u0026nbsp; Gary also represents companies in transactional matters including distribution and purchasing agreements, pharmacy agreements, clinical trial agreements, payor agreements, manufacturing and supply agreements, physician agreements, research agreements and co-promotion agreements.\u003c/p\u003e\n\u003cp\u003ePreviously, Gary was in-house counsel at Eli Lilly and Company, where he had global legal, regulatory and compliance responsibility for the company's top-selling pharmaceutical product at the time.\u003c/p\u003e\n\u003cp\u003eA frequent author and speaker on regulatory and compliance matters, Gary has been recognized for multiple years by\u0026nbsp;\u003cem\u003eSuper Lawyers Washington, DC\u003c/em\u003e.\u003c/p\u003e","slug":"gary-messplay","email":"gmessplay@kslaw.com","phone":"+1 703 973 7500","matters":["\u003cp\u003eDeveloped customized, comprehensive healthcare compliance programs for numerous \u003cstrong data-redactor-tag=\"strong\"\u003edrug and medical device companies.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eServed as outside general counsel to \u003cstrong data-redactor-tag=\"strong\"\u003especialty pharmaceutical companies and emerging drug and device companies.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eLed significant multi-year investigation for \u003cstrong data-redactor-tag=\"strong\"\u003ea large pharmaceutical company\u003c/strong\u003e involving complex data integrity issues related to their bioanalytics laboratory.\u003c/p\u003e","\u003cp\u003eAdvised numerous \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e related to product commercialization, including advertising and promotion, First Amendment issues, interactions with payors and responding to FDA enforcement.\u003c/p\u003e","\u003cp\u003eConducted a significant number of compliance investigations on behalf of \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies,\u003c/strong\u003e including large multinational investigations, involving off-label promotion, violations of the federal Anti-Kickback Statute and FCPA, whistleblower reports, clinical trial noncompliance, cGMP violations, GLP violations and PDMA/drug sampling.\u003c/p\u003e","\u003cp\u003eRepresented Board of Directors of \u003cstrong data-redactor-tag=\"strong\"\u003epublicly traded pharmaceutical company\u003c/strong\u003e in connection with an investigation involving the company's chief executive officer related to suspected violations of the federal Anti-Kickback Statute.\u003c/p\u003e","\u003cp\u003eAdvised \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e on all aspects of compliance with their corporate integrity agreements.\u003c/p\u003e","\u003cp\u003eAdvised numerous \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical companies\u003c/strong\u003e on drug-approval strategies involving NDAs, product life cycle management, Hatch-Waxman and Orange Book issues.\u003c/p\u003e","\u003cp\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea specialty pharmaceutical company\u003c/strong\u003e in response to a petition filed by a public citizen seeking FDA withdrawal of popular pain medication.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in connection with FDA, OCI, Department of Justice, SEC and congressional investigations.\u003c/p\u003e","\u003cp\u003eAdvised \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e related to clinical trial regulatory and compliance issues.\u003c/p\u003e","\u003cp\u003eAssisted \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical companies\u003c/strong\u003e in developing and implementing specialty pharmacy programs.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in connection with adverse FDA inspections, including responding to 483s and warning letters.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in transactional matters involving clinical trial agreements, CRO agreements, distribution agreements, specialty pharmacy agreements and all types of services agreements.\u003c/p\u003e","\u003cp\u003eLed numerous regulatory and compliance due diligence teams in \u003cstrong data-redactor-tag=\"strong\"\u003edrug, device, tobacco and food transactions.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in connection with competitor disputes, including serving as trial counsel in major Lanham Act litigation.\u003c/p\u003e","\u003cp\u003eAdvised \u003cstrong data-redactor-tag=\"strong\"\u003edrug, biotechnology, device, food and tobacco companies\u003c/strong\u003e on legislative matters including drafting and commenting on legislation.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":2,"guid":"2.capabilities","index":0,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":4,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":5,"source":"smartTags"},{"id":17,"guid":"17.capabilities","index":6,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":7,"source":"capabilities"},{"id":109,"guid":"109.capabilities","index":8,"source":"capabilities"},{"id":1193,"guid":"1193.smart_tags","index":9,"source":"smartTags"}],"is_active":true,"last_name":"Messplay","nick_name":"Gary","clerkships":[],"first_name":"Gary","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"C.","name_suffix":"","recognitions":[{"title":"","detail":"Super Lawyers, 2014, 2015 \u0026 2016"}],"linked_in_url":"https://www.linkedin.com/in/gary-messplay-45599b61/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eGary Messplay specializes in advising life science companies on regulatory, compliance and transactional matters. A partner in our nationally recognized FDA and Life Sciences practice, Gary has almost 30 years of experience representing large multinational pharmaceutical and medical-device companies, as well as emerging companies.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGary advices clients in matters relating to the approval and commercialization of products that are regulated by the Food\u0026nbsp;and Drug Administration and other federal and state agencies.\u0026nbsp; Gary has substantial experience advising clients on all aspects of product approvals; product launches and commercialization including advertising and promotion; leading compliance-related investigations; developing and implementing regulatory and healthcare compliance programs; advising on patient support programs; and managing competitor disputes.\u0026nbsp; In addition, Gary regularly advises clients on matters relating to healthcare fraud and abuse, clinical trials, informed consent, drug safety issues, product liability, recalls, responding to 483s, warning letters and complete response letters, drug and device quality and manufacturing issues, and life cycle management.\u0026nbsp; Gary also represents companies in transactional matters including distribution and purchasing agreements, pharmacy agreements, clinical trial agreements, payor agreements, manufacturing and supply agreements, physician agreements, research agreements and co-promotion agreements.\u003c/p\u003e\n\u003cp\u003ePreviously, Gary was in-house counsel at Eli Lilly and Company, where he had global legal, regulatory and compliance responsibility for the company's top-selling pharmaceutical product at the time.\u003c/p\u003e\n\u003cp\u003eA frequent author and speaker on regulatory and compliance matters, Gary has been recognized for multiple years by\u0026nbsp;\u003cem\u003eSuper Lawyers Washington, DC\u003c/em\u003e.\u003c/p\u003e","matters":["\u003cp\u003eDeveloped customized, comprehensive healthcare compliance programs for numerous \u003cstrong data-redactor-tag=\"strong\"\u003edrug and medical device companies.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eServed as outside general counsel to \u003cstrong data-redactor-tag=\"strong\"\u003especialty pharmaceutical companies and emerging drug and device companies.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eLed significant multi-year investigation for \u003cstrong data-redactor-tag=\"strong\"\u003ea large pharmaceutical company\u003c/strong\u003e involving complex data integrity issues related to their bioanalytics laboratory.\u003c/p\u003e","\u003cp\u003eAdvised numerous \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e related to product commercialization, including advertising and promotion, First Amendment issues, interactions with payors and responding to FDA enforcement.\u003c/p\u003e","\u003cp\u003eConducted a significant number of compliance investigations on behalf of \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies,\u003c/strong\u003e including large multinational investigations, involving off-label promotion, violations of the federal Anti-Kickback Statute and FCPA, whistleblower reports, clinical trial noncompliance, cGMP violations, GLP violations and PDMA/drug sampling.\u003c/p\u003e","\u003cp\u003eRepresented Board of Directors of \u003cstrong data-redactor-tag=\"strong\"\u003epublicly traded pharmaceutical company\u003c/strong\u003e in connection with an investigation involving the company's chief executive officer related to suspected violations of the federal Anti-Kickback Statute.\u003c/p\u003e","\u003cp\u003eAdvised \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e on all aspects of compliance with their corporate integrity agreements.\u003c/p\u003e","\u003cp\u003eAdvised numerous \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical companies\u003c/strong\u003e on drug-approval strategies involving NDAs, product life cycle management, Hatch-Waxman and Orange Book issues.\u003c/p\u003e","\u003cp\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea specialty pharmaceutical company\u003c/strong\u003e in response to a petition filed by a public citizen seeking FDA withdrawal of popular pain medication.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in connection with FDA, OCI, Department of Justice, SEC and congressional investigations.\u003c/p\u003e","\u003cp\u003eAdvised \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e related to clinical trial regulatory and compliance issues.\u003c/p\u003e","\u003cp\u003eAssisted \u003cstrong data-redactor-tag=\"strong\"\u003epharmaceutical companies\u003c/strong\u003e in developing and implementing specialty pharmacy programs.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in connection with adverse FDA inspections, including responding to 483s and warning letters.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in transactional matters involving clinical trial agreements, CRO agreements, distribution agreements, specialty pharmacy agreements and all types of services agreements.\u003c/p\u003e","\u003cp\u003eLed numerous regulatory and compliance due diligence teams in \u003cstrong data-redactor-tag=\"strong\"\u003edrug, device, tobacco and food transactions.\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003edrug and device companies\u003c/strong\u003e in connection with competitor disputes, including serving as trial counsel in major Lanham Act litigation.\u003c/p\u003e","\u003cp\u003eAdvised \u003cstrong data-redactor-tag=\"strong\"\u003edrug, biotechnology, device, food and tobacco companies\u003c/strong\u003e on legislative matters including drafting and commenting on legislation.\u003c/p\u003e"],"recognitions":[{"title":"","detail":"Super Lawyers, 2014, 2015 \u0026 2016"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4357}]},"capability_group_id":2},"created_at":"2025-05-26T04:54:29.000Z","updated_at":"2025-05-26T04:54:29.000Z","searchable_text":"Messplay{{ FIELD }}{:title=\u0026gt;\"\", :detail=\u0026gt;\"Super Lawyers, 2014, 2015 \u0026amp; 2016\"}{{ FIELD }}Developed customized, comprehensive healthcare compliance programs for numerous drug and medical device companies.{{ FIELD }}Served as outside general counsel to specialty pharmaceutical companies and emerging drug and device companies.{{ FIELD }}Led significant multi-year investigation for a large pharmaceutical company involving complex data integrity issues related to their bioanalytics laboratory.{{ FIELD }}Advised numerous drug and device companies related to product commercialization, including advertising and promotion, First Amendment issues, interactions with payors and responding to FDA enforcement.{{ FIELD }}Conducted a significant number of compliance investigations on behalf of drug and device companies, including large multinational investigations, involving off-label promotion, violations of the federal Anti-Kickback Statute and FCPA, whistleblower reports, clinical trial noncompliance, cGMP violations, GLP violations and PDMA/drug sampling.{{ FIELD }}Represented Board of Directors of publicly traded pharmaceutical company in connection with an investigation involving the company's chief executive officer related to suspected violations of the federal Anti-Kickback Statute.{{ FIELD }}Advised drug and device companies on all aspects of compliance with their corporate integrity agreements.{{ FIELD }}Advised numerous pharmaceutical companies on drug-approval strategies involving NDAs, product life cycle management, Hatch-Waxman and Orange Book issues.{{ FIELD }}Successfully represented a specialty pharmaceutical company in response to a petition filed by a public citizen seeking FDA withdrawal of popular pain medication.{{ FIELD }}Represented drug and device companies in connection with FDA, OCI, Department of Justice, SEC and congressional investigations.{{ FIELD }}Advised drug and device companies related to clinical trial regulatory and compliance issues.{{ FIELD }}Assisted pharmaceutical companies in developing and implementing specialty pharmacy programs.{{ FIELD }}Represented drug and device companies in connection with adverse FDA inspections, including responding to 483s and warning letters.{{ FIELD }}Represented drug and device companies in transactional matters involving clinical trial agreements, CRO agreements, distribution agreements, specialty pharmacy agreements and all types of services agreements.{{ FIELD }}Led numerous regulatory and compliance due diligence teams in drug, device, tobacco and food transactions.{{ FIELD }}Represented drug and device companies in connection with competitor disputes, including serving as trial counsel in major Lanham Act litigation.{{ FIELD }}Advised drug, biotechnology, device, food and tobacco companies on legislative matters including drafting and commenting on legislation.{{ FIELD }}Gary Messplay specializes in advising life science companies on regulatory, compliance and transactional matters. A partner in our nationally recognized FDA and Life Sciences practice, Gary has almost 30 years of experience representing large multinational pharmaceutical and medical-device companies, as well as emerging companies.\nGary advices clients in matters relating to the approval and commercialization of products that are regulated by the Food and Drug Administration and other federal and state agencies.  Gary has substantial experience advising clients on all aspects of product approvals; product launches and commercialization including advertising and promotion; leading compliance-related investigations; developing and implementing regulatory and healthcare compliance programs; advising on patient support programs; and managing competitor disputes.  In addition, Gary regularly advises clients on matters relating to healthcare fraud and abuse, clinical trials, informed consent, drug safety issues, product liability, recalls, responding to 483s, warning letters and complete response letters, drug and device quality and manufacturing issues, and life cycle management.  Gary also represents companies in transactional matters including distribution and purchasing agreements, pharmacy agreements, clinical trial agreements, payor agreements, manufacturing and supply agreements, physician agreements, research agreements and co-promotion agreements.\nPreviously, Gary was in-house counsel at Eli Lilly and Company, where he had global legal, regulatory and compliance responsibility for the company's top-selling pharmaceutical product at the time.\nA frequent author and speaker on regulatory and compliance matters, Gary has been recognized for multiple years by Super Lawyers Washington, DC. Partner  Super Lawyers, 2014, 2015 \u0026amp; 2016 District of Columbia Indiana Developed customized, comprehensive healthcare compliance programs for numerous drug and medical device companies. Served as outside general counsel to specialty pharmaceutical companies and emerging drug and device companies. Led significant multi-year investigation for a large pharmaceutical company involving complex data integrity issues related to their bioanalytics laboratory. Advised numerous drug and device companies related to product commercialization, including advertising and promotion, First Amendment issues, interactions with payors and responding to FDA enforcement. Conducted a significant number of compliance investigations on behalf of drug and device companies, including large multinational investigations, involving off-label promotion, violations of the federal Anti-Kickback Statute and FCPA, whistleblower reports, clinical trial noncompliance, cGMP violations, GLP violations and PDMA/drug sampling. Represented Board of Directors of publicly traded pharmaceutical company in connection with an investigation involving the company's chief executive officer related to suspected violations of the federal Anti-Kickback Statute. Advised drug and device companies on all aspects of compliance with their corporate integrity agreements. Advised numerous pharmaceutical companies on drug-approval strategies involving NDAs, product life cycle management, Hatch-Waxman and Orange Book issues. Successfully represented a specialty pharmaceutical company in response to a petition filed by a public citizen seeking FDA withdrawal of popular pain medication. Represented drug and device companies in connection with FDA, OCI, Department of Justice, SEC and congressional investigations. Advised drug and device companies related to clinical trial regulatory and compliance issues. Assisted pharmaceutical companies in developing and implementing specialty pharmacy programs. Represented drug and device companies in connection with adverse FDA inspections, including responding to 483s and warning letters. Represented drug and device companies in transactional matters involving clinical trial agreements, CRO agreements, distribution agreements, specialty pharmacy agreements and all types of services agreements. Led numerous regulatory and compliance due diligence teams in drug, device, tobacco and food transactions. Represented drug and device companies in connection with competitor disputes, including serving as trial counsel in major Lanham Act litigation. Advised drug, biotechnology, device, food and tobacco companies on legislative matters including drafting and commenting on legislation.","searchable_name":"Gary C. Messplay","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":426362,"version":1,"owner_type":"Person","owner_id":2895,"payload":{"bio":"\u003cp\u003eGreg Massoni joins King \u0026amp; Spalding as a consultant with the Government Advocacy practice, having served as one of nine founding members of the Baltimore Office of Womble Carlyle Sandridge \u0026amp; Rice in the Strategic and Crisis Communications Team.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGreg served as Deputy Director of Communications and Press Secretary to Governor Robert L. Ehrlich Jr from 2002-2007. As Press Secretary, his responsibilities included dealing with the media, managing press offices in 18 Executive Agencies throughout the State of Maryland, and overseeing scheduling, special events, and messaging for the Ehrlich Administration. Greg also served as Senior Advisor in the 2010 campaign.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs an Emmy Award winning Producer/Director whose resume includes WJLA TV in Washington, D.C., WMAR TV in Baltimore, as the Executive Producer of Orioles Baseball and WBFF TV in Baltimore as Director of Captain Chesapeake. Currently Greg serves a Producer/Director of Raven Gameday productions.\u003c/p\u003e","slug":"greg-massoni","email":"gmassoni@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"}],"is_active":true,"last_name":"Massoni","nick_name":"Greg","clerkships":[],"first_name":"Greg","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"H. N.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":11,"translated_fields":{"en":{"bio":"\u003cp\u003eGreg Massoni joins King \u0026amp; Spalding as a consultant with the Government Advocacy practice, having served as one of nine founding members of the Baltimore Office of Womble Carlyle Sandridge \u0026amp; Rice in the Strategic and Crisis Communications Team.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eGreg served as Deputy Director of Communications and Press Secretary to Governor Robert L. Ehrlich Jr from 2002-2007. As Press Secretary, his responsibilities included dealing with the media, managing press offices in 18 Executive Agencies throughout the State of Maryland, and overseeing scheduling, special events, and messaging for the Ehrlich Administration. Greg also served as Senior Advisor in the 2010 campaign.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAs an Emmy Award winning Producer/Director whose resume includes WJLA TV in Washington, D.C., WMAR TV in Baltimore, as the Executive Producer of Orioles Baseball and WBFF TV in Baltimore as Director of Captain Chesapeake. Currently Greg serves a Producer/Director of Raven Gameday productions.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{},"capability_group_id":2},"created_at":"2025-05-26T04:51:51.000Z","updated_at":"2025-05-26T04:51:51.000Z","searchable_text":"Massoni{{ FIELD }}Greg Massoni joins King \u0026amp; Spalding as a consultant with the Government Advocacy practice, having served as one of nine founding members of the Baltimore Office of Womble Carlyle Sandridge \u0026amp; Rice in the Strategic and Crisis Communications Team.\nGreg served as Deputy Director of Communications and Press Secretary to Governor Robert L. Ehrlich Jr from 2002-2007. As Press Secretary, his responsibilities included dealing with the media, managing press offices in 18 Executive Agencies throughout the State of Maryland, and overseeing scheduling, special events, and messaging for the Ehrlich Administration. Greg also served as Senior Advisor in the 2010 campaign. \nAs an Emmy Award winning Producer/Director whose resume includes WJLA TV in Washington, D.C., WMAR TV in Baltimore, as the Executive Producer of Orioles Baseball and WBFF TV in Baltimore as Director of Captain Chesapeake. Currently Greg serves a Producer/Director of Raven Gameday productions. Consultant","searchable_name":"Greg H. N. Massoni","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":436461,"version":1,"owner_type":"Person","owner_id":4972,"payload":{"bio":"\u003cp\u003eFormer Congressman Kendrick B. Meek is a senior advisor in King \u0026amp; Spalding\u0026rsquo;s Government Advocacy and Public Policy Group.\u0026nbsp; He advises a diverse group of companies in the healthcare, technology, higher education, agriculture, energy, and financial services sectors on policy and political strategy development and third-party public policy engagement.\u0026nbsp; He also advises top-level executives on managing government relations teams and provides strategic advice on philanthropic efforts with third-party groups.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eHaving served as a member of the U.S. House of Representatives, the Florida State Legislature, and as Special Representative to the United Nations, Congressman Meek has honed his skills over his long tenure in politics and has earned a reputation as a trusted advisor to these companies, public policy organizations, and Members of Congress on both sides of the aisle.\u003c/p\u003e\n\u003cp\u003eFrom 2002 to 2010, Congressman Kendrick B. Meek served as a member of the U.S. House of Representatives representing Broward and Miami-Dade Counties. During his tenure in Washington, Congressman Meek\u0026rsquo;s open-minded and bipartisan outlook allowed him to navigate a broad cross-section of Congress to achieve remarkable results for his constituents. \u0026nbsp;Building on his strong legislative record in the Florida Senate and Florida House of Representatives, Congressman Meek was able to secure a spot on the House Ways and Means Committee. \u0026nbsp;In that capacity, he was successful in sponsoring and passing legislation focused on tax, trade, and healthcare issues.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn addition to legislative and executive branch political strategy, Congressman Meek assists his clients in achieving their legislative and community goodwill goals through his close relationships with non-profit and advocacy groups and with his high-level contacts at the federal, state, and local levels.\u003c/p\u003e\n\u003cp\u003eCongressman Meek also has a robust background in homeland security and international affairs.\u0026nbsp; While in Congress, he was appointed to the NATO Parliamentary Assembly, and served on both the Armed Services and Homeland Security committees.\u0026nbsp; In 2011, after leaving Congress, President Obama appointed Congressman Meek as Special Representative to the United Nations.\u003c/p\u003e\n\u003cp\u003eCongressman Meek currently serves as Director Emeritus of the Congressional Black Caucus Foundation and is one of only two former Members to hold this position.\u003c/p\u003e","slug":"kendrick-meek","email":"kmeek@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":687,"guid":"687.smart_tags","index":1,"source":"smartTags"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":3,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":4,"source":"capabilities"},{"id":37,"guid":"37.capabilities","index":5,"source":"capabilities"},{"id":25,"guid":"25.capabilities","index":6,"source":"capabilities"},{"id":124,"guid":"124.capabilities","index":7,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Meek","nick_name":"Kendrick","clerkships":[],"first_name":"Kendrick","title_rank":9999,"updated_by":202,"law_schools":[],"middle_name":"B.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":74,"translated_fields":{"en":{"bio":"\u003cp\u003eFormer Congressman Kendrick B. Meek is a senior advisor in King \u0026amp; Spalding\u0026rsquo;s Government Advocacy and Public Policy Group.\u0026nbsp; He advises a diverse group of companies in the healthcare, technology, higher education, agriculture, energy, and financial services sectors on policy and political strategy development and third-party public policy engagement.\u0026nbsp; He also advises top-level executives on managing government relations teams and provides strategic advice on philanthropic efforts with third-party groups.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eHaving served as a member of the U.S. House of Representatives, the Florida State Legislature, and as Special Representative to the United Nations, Congressman Meek has honed his skills over his long tenure in politics and has earned a reputation as a trusted advisor to these companies, public policy organizations, and Members of Congress on both sides of the aisle.\u003c/p\u003e\n\u003cp\u003eFrom 2002 to 2010, Congressman Kendrick B. Meek served as a member of the U.S. House of Representatives representing Broward and Miami-Dade Counties. During his tenure in Washington, Congressman Meek\u0026rsquo;s open-minded and bipartisan outlook allowed him to navigate a broad cross-section of Congress to achieve remarkable results for his constituents. \u0026nbsp;Building on his strong legislative record in the Florida Senate and Florida House of Representatives, Congressman Meek was able to secure a spot on the House Ways and Means Committee. \u0026nbsp;In that capacity, he was successful in sponsoring and passing legislation focused on tax, trade, and healthcare issues.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn addition to legislative and executive branch political strategy, Congressman Meek assists his clients in achieving their legislative and community goodwill goals through his close relationships with non-profit and advocacy groups and with his high-level contacts at the federal, state, and local levels.\u003c/p\u003e\n\u003cp\u003eCongressman Meek also has a robust background in homeland security and international affairs.\u0026nbsp; While in Congress, he was appointed to the NATO Parliamentary Assembly, and served on both the Armed Services and Homeland Security committees.\u0026nbsp; In 2011, after leaving Congress, President Obama appointed Congressman Meek as Special Representative to the United Nations.\u003c/p\u003e\n\u003cp\u003eCongressman Meek currently serves as Director Emeritus of the Congressional Black Caucus Foundation and is one of only two former Members to hold this position.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6520}]},"capability_group_id":2},"created_at":"2025-09-02T04:55:07.000Z","updated_at":"2025-09-02T04:55:07.000Z","searchable_text":"Meek{{ FIELD }}Former Congressman Kendrick B. Meek is a senior advisor in King \u0026amp; Spalding’s Government Advocacy and Public Policy Group.  He advises a diverse group of companies in the healthcare, technology, higher education, agriculture, energy, and financial services sectors on policy and political strategy development and third-party public policy engagement.  He also advises top-level executives on managing government relations teams and provides strategic advice on philanthropic efforts with third-party groups. \nHaving served as a member of the U.S. House of Representatives, the Florida State Legislature, and as Special Representative to the United Nations, Congressman Meek has honed his skills over his long tenure in politics and has earned a reputation as a trusted advisor to these companies, public policy organizations, and Members of Congress on both sides of the aisle.\nFrom 2002 to 2010, Congressman Kendrick B. Meek served as a member of the U.S. House of Representatives representing Broward and Miami-Dade Counties. During his tenure in Washington, Congressman Meek’s open-minded and bipartisan outlook allowed him to navigate a broad cross-section of Congress to achieve remarkable results for his constituents.  Building on his strong legislative record in the Florida Senate and Florida House of Representatives, Congressman Meek was able to secure a spot on the House Ways and Means Committee.  In that capacity, he was successful in sponsoring and passing legislation focused on tax, trade, and healthcare issues. \nIn addition to legislative and executive branch political strategy, Congressman Meek assists his clients in achieving their legislative and community goodwill goals through his close relationships with non-profit and advocacy groups and with his high-level contacts at the federal, state, and local levels.\nCongressman Meek also has a robust background in homeland security and international affairs.  While in Congress, he was appointed to the NATO Parliamentary Assembly, and served on both the Armed Services and Homeland Security committees.  In 2011, after leaving Congress, President Obama appointed Congressman Meek as Special Representative to the United Nations.\nCongressman Meek currently serves as Director Emeritus of the Congressional Black Caucus Foundation and is one of only two former Members to hold this position. Senior Advisor Florida A\u0026amp;M University  Director Emeritus, Congressional Black Caucus Foundation Board of Directors, Hospice Foundation of America Board of Directors, Close Up Foundation Board of Directors, Claude Pepper Foundation","searchable_name":"Kendrick B. Meek","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426608,"version":1,"owner_type":"Person","owner_id":5107,"payload":{"bio":"\u003cp\u003eFormer Office of Management and Budget Director and Chairman of the Federal Trade Commission Jim Miller III is a Senior Advisor in King \u0026amp; Spalding\u0026rsquo;s Government Advocacy and Public Policy practice and an expert on public policy issues. He applies his deep knowledge of regulatory, economic, legal and political issues to benefit corporate clients around the world.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJim\u0026rsquo;s public policy experience spans more than 35 years. \u0026nbsp;He is a former U.S. government official and economist who served as chairman of the Federal Trade Commission between 1981 and 1985 and as Budget Director for President Ronald Reagan between 1985 and 1988. He was the first administrator of the Office of Information and Regulatory Affairs and the executive director of Vice President George H. W. Bush's Presidential Task Force on Regulatory Relief. He was also appointed by President Bush to be a member of the Board of Governors of the U.S. Postal Service, where he was later elected chair.\u003c/p\u003e\n\u003cp\u003eJim\u0026rsquo;s breadth of experience gives his clients invaluable insight on a range of issues including federal/state regulatory programs, campaign finance, tax structure, industrial organization, antitrust, intellectual property,\u0026nbsp; fiscal finance, federal/state spending, deficits and public choice. He has positioned himself as a subject matter expert and is frequently called upon by major news outlets to comment on public issues.\u003c/p\u003e\n\u003cp\u003eJim is a distinguished fellow at the Center for Study of Public Choice at George Mason University and a senior fellow of the Hoover Institution at Stanford University.\u003c/p\u003e","slug":"jim-miller","email":"jmiller@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"}],"is_active":true,"last_name":"Miller","nick_name":"Jim","clerkships":[],"first_name":"Jim","title_rank":9999,"updated_by":35,"law_schools":[],"middle_name":"C.","name_suffix":"III","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":74,"translated_fields":{"en":{"bio":"\u003cp\u003eFormer Office of Management and Budget Director and Chairman of the Federal Trade Commission Jim Miller III is a Senior Advisor in King \u0026amp; Spalding\u0026rsquo;s Government Advocacy and Public Policy practice and an expert on public policy issues. He applies his deep knowledge of regulatory, economic, legal and political issues to benefit corporate clients around the world.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eJim\u0026rsquo;s public policy experience spans more than 35 years. \u0026nbsp;He is a former U.S. government official and economist who served as chairman of the Federal Trade Commission between 1981 and 1985 and as Budget Director for President Ronald Reagan between 1985 and 1988. He was the first administrator of the Office of Information and Regulatory Affairs and the executive director of Vice President George H. W. Bush's Presidential Task Force on Regulatory Relief. He was also appointed by President Bush to be a member of the Board of Governors of the U.S. Postal Service, where he was later elected chair.\u003c/p\u003e\n\u003cp\u003eJim\u0026rsquo;s breadth of experience gives his clients invaluable insight on a range of issues including federal/state regulatory programs, campaign finance, tax structure, industrial organization, antitrust, intellectual property,\u0026nbsp; fiscal finance, federal/state spending, deficits and public choice. He has positioned himself as a subject matter expert and is frequently called upon by major news outlets to comment on public issues.\u003c/p\u003e\n\u003cp\u003eJim is a distinguished fellow at the Center for Study of Public Choice at George Mason University and a senior fellow of the Hoover Institution at Stanford University.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{},"capability_group_id":2},"created_at":"2025-05-26T04:55:17.000Z","updated_at":"2025-05-26T04:55:17.000Z","searchable_text":"Miller{{ FIELD }}Former Office of Management and Budget Director and Chairman of the Federal Trade Commission Jim Miller III is a Senior Advisor in King \u0026amp; Spalding’s Government Advocacy and Public Policy practice and an expert on public policy issues. He applies his deep knowledge of regulatory, economic, legal and political issues to benefit corporate clients around the world.\nJim’s public policy experience spans more than 35 years.  He is a former U.S. government official and economist who served as chairman of the Federal Trade Commission between 1981 and 1985 and as Budget Director for President Ronald Reagan between 1985 and 1988. He was the first administrator of the Office of Information and Regulatory Affairs and the executive director of Vice President George H. W. Bush's Presidential Task Force on Regulatory Relief. He was also appointed by President Bush to be a member of the Board of Governors of the U.S. Postal Service, where he was later elected chair.\nJim’s breadth of experience gives his clients invaluable insight on a range of issues including federal/state regulatory programs, campaign finance, tax structure, industrial organization, antitrust, intellectual property,  fiscal finance, federal/state spending, deficits and public choice. He has positioned himself as a subject matter expert and is frequently called upon by major news outlets to comment on public issues.\nJim is a distinguished fellow at the Center for Study of Public Choice at George Mason University and a senior fellow of the Hoover Institution at Stanford University. Senior Advisor University of Georgia University of Georgia School of Law University of Virginia University of Virginia School of Law","searchable_name":"Jim C. Miller III","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":35,"capability_group_featured":null,"home_page_featured":null}]}}